Recursion Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while United States Natural Gas Fund trades at $10.22. Which is the better fit depends on your goals.
| RXRX | UNG | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Commodities - Energy |
52-Week High | $6.79 | $16.90 |
52-Week Low | $2.84 | $9.63 |
Enterprise Value | $1.33B | — |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
UNG, tracking U.S. natural gas futures, trades at $10.24 with a 0.99% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights steady natural gas prices amid weather-driven demand shifts and geopolitical tensions. The fund lacks traditional company fundamentals as it is an ETF, with financial ratios unavailable.
The outlook is cautious due to bearish technicals and volatile commodity exposure. Opportunities exist if natural gas demand surges from weather or LNG exports, but risks include price swings from storage levels and production changes. Investors should weigh this as a speculative play on energy markets.
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →